In KRAS G12C-positive advanced NSCLC
This is my non-small
REVOLUTION
Focusing on yourself is your boldest move yet. Partnering with your care team and experiencing KRAZATI® (adagrasib)—an oral, targeted therapy—can keep the focus on you and your NSCLC.
KRAZATI doesn’t require a break in treatment before starting, which means you can continue fighting your cancer immediately after your first-line therapy ends, without a gap in treatment.*
*Based on the KRAZATI Prescribing Information; however, in the study, patients took a 2-week break after their most recent cancer treatment, including immunotherapy.